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Background: Transcatheter Aortic Valve Implantation (TAVI) has revolutionized the treatment of aortic valve stenosis of high surgical risk. Research 
has focussed on those undergoing TAVI. We have comprehensively studied all TAVI candidates, their pathway and the decision process.
Methods: All patients (n = 109) referred to the Papworth multi-disciplinary team (MDT) for a TAVI were prospectively enrolled. Baseline 
demographics and outcomes were recorded.
Results: Patients (n=26) awaiting treatment / final MDT decision were excluded. 17 patients were treated by TAVI (7 transfemoral, 10 transapical), 
27 by conventional surgical AVR (csAVR), 9 with balloon valvuloplasty (BAV) and 30 medically. There were no differences in baseline characteristics 
(but for an excess of prior CABG in the TAVI group vs. csAVR (13/17 vs. 3/27; p <0.001)) nor in logistic EuroSCORE (ES): TAVI: 18.5% (IQR 8.4 - 
27.1%); csAVR: 12.1% (7.5 - 27.1%); BAV: 30.0% (12.8 - 39.0%); medical: 20.4% (10.6 - 40.0%): p= 0.35. 30 day mortalities were: TAVI: 0/17; 
csAVR: 1/25; BAV: 1/9; medical: 8/30. Adjusting for ES, the observed / expected 30 day mortality indices were: TAVI: 0; csAVR: 0.33; BAV: 0.37; 
medical: 1.31. Valve replacement patients (TAVI & csAVR) had a lower 30 day mortality than palliative treatment (BAV & medical): 2.38% vs. 25.6%, 
p = 0.003. This survival benefit persisted upon medium term follow up, log rank p<0.001 (see figure).
Conclusion: An MDT approach to TAVI case selection facilitates a low mortality despite high predicted risk.
